Literature DB >> 14501697

Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage.

Sam S Chang1, J Matthew Hassan, Michael S Cookson, Nancy Wells, Joseph A Smith.   

Abstract

PURPOSE: While radical cystectomy remains the treatment of choice for invasive transitional cell carcinoma, the importance of its timing has been increasingly scrutinized. We determined whether the interval between diagnosis of muscle invasion and definitive radical cystectomy influenced pathological staging outcome.
MATERIALS AND METHODS: Of the 303 patients who underwent radical cystectomy from January 1998 to December 2001, 153 were diagnosed with muscle invasive transitional cell carcinoma at transurethral resection. Charts were reviewed for pathological stage, demographics and time between diagnosis of muscle invasion and radical cystectomy.
RESULTS: Mean patient age was 67.2 years (range 35 to 88) with the majority (121 of 153, 79%) being male. At the time of cystectomy, 68 of 153 (44%) patients had organ confined disease (pT2B or lower), while node positive disease was found in 58 of 153 patients (38%). Mean time from transurethral resection diagnosis of muscle invasive disease until cystectomy was 63 days (range 8 to 473). A statistically significant correlation existed between time of diagnosis and cystectomy, and final pathological stage. Specifically, those patients with an interval greater than 90 days were more likely to have pT3 or higher, nonorgan confined disease compared to those patients undergoing cystectomy before 90 days (81% versus 52%, p = 0.01). Furthermore, those patients with organ confined disease had a significantly shorter mean time between diagnosis and cystectomy of 47.5 days versus 75.1 days for nonorgan confined disease (t test p = 0.02).
CONCLUSIONS: In patients with muscle invasion at diagnosis, a delay in surgery is associated with more advanced pathological stage, especially when the delay is longer than 90 days. While appropriate time should be given for consideration of options and pretreatment evaluation, undue delay may compromise cancer control.

Entities:  

Mesh:

Year:  2003        PMID: 14501697     DOI: 10.1097/01.ju.0000086828.26001.ca

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  35 in total

Review 1.  Management of carcinoma in situ of the bladder: best practice and recent developments.

Authors:  Dominic H Tang; Sam S Chang
Journal:  Ther Adv Urol       Date:  2015-12

2.  Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy.

Authors:  Thomas F Chromecki; Julian Mauermann; Eugene K Cha; Robert S Svatek; Harun Fajkovic; Pierre I Karakiewicz; Yair Lotan; Derya Tilki; Patrick J Bastian; Bjoern G Volkmer; Francesco Montorsi; Wassim Kassouf; Giacomo Novara; Hans-Martin Fritsche; Vincenzo Ficarra; Christian G Stief; Colin P Dinney; Eila Skinner; Karl Pummer; Yves Fradet; Shahrokh F Shariat
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

3.  Clinical trials: nationally representative data in urology.

Authors:  Jay B Shah; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

Review 4.  Bladder cancer in the elderly.

Authors:  Shahrokh F Shariat; Matthew Milowsky; Michael J Droller
Journal:  Urol Oncol       Date:  2009 Nov-Dec       Impact factor: 3.498

Review 5.  Improvements in safety and recovery following cystectomy: reassessing the role of pre-operative bowel preparation and interventions to speed return of post-operative bowel function.

Authors:  Harras B Zaid; Samuel D Kaffenberger; Sam S Chang
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

Review 6.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

7.  Variations in reconstruction after radical cystectomy.

Authors:  John L Gore; Christopher S Saigal; Jan M Hanley; Matthias Schonlau; Mark S Litwin
Journal:  Cancer       Date:  2006-08-15       Impact factor: 6.860

8.  Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer.

Authors:  H Barton Grossman; Michael A O'Donnell; Michael S Cookson; Richard E Greenberg; Thomas E Keane
Journal:  Rev Urol       Date:  2008

9.  Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis.

Authors:  John L Gore; Julie Lai; Claude M Setodji; Mark S Litwin; Christopher S Saigal
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

Review 10.  [Cystectomy in the elderly patient].

Authors:  G Bartsch; K Gust; S Vallo; C Bartsch; I Tsaur; J Mani; A Haferkamp
Journal:  Urologe A       Date:  2013-06       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.